# Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma

> **NCT00323830** · PHASE3 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 458 (actual)

## Conditions studied

- Gastric Cancer
- Surgery

## Interventions

- **DRUG:** Capecitabine, cisplatin, Radiotherapy (+/-)

## Key facts

- **NCT ID:** NCT00323830
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2008-04
- **Final completion:** 2011-04
- **Target enrollment:** 458 (ACTUAL)
- **Last updated:** 2011-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00323830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00323830, "Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00323830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*